Roivant Sciences Limited
ROIV
ISIN BMG762791017 / Valor 113331044
Roivant Sciences Limited
UMushroom community rating:
About company
Roivant Sciences Limited is a biopharmaceutical company that focuses on developing and commercializing innovative therapies by leveraging technology to enhance drug development processes. The company aims to transform the pharmaceutical industry by integrating technology and data analytics into its operations, positioning itself as a pioneering PharmaTech entity. Roivant operates through a unique model of creating subsidiary companies, known as "Vants," each dedicated to specific therapeutic areas or technologies. This approach allows Roivant to efficiently manage and advance a diverse portfolio of drug candidates across various stages of development. The company is known for its strategic partnerships and collaborations, which help accelerate the development and commercialization of its therapies. Roivant's business strategy is centered on addressing unmet medical needs and improving patient outcomes through the application of cutting-edge technology and innovative drug development methodologies.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (15.11.2025):
Roivant Sciences Limited reported its financial results for the fourth quarter and fiscal year ended March 31, 2025. The company showcased a robust cash position of $4.9 billion, significant increases in research and development expenses, and a notable share repurchase of $1.3 billion that reduced outstanding shares by 14% compared to the previous year. These financial updates coincide with progressive program developments and operational enhancements across its portfolio.
Cash Position & Share Repurchase
As of March 31, 2025, Roivant Sciences Limited had consolidated cash, cash equivalents, restricted cash, and marketable securities totaling $4.9 billion. The company also repurchased $1.3 billion of its shares during the quarter, reducing its outstanding shares by 14% compared to March 31, 2024.
Research and Development Investments
The fourth quarter R&D expenses increased by $37.7 million to $145.2 million, driven by higher program-specific costs and increased personnel-related expenses particularly at Immunovant. For the full fiscal year ended March 31, 2025, R&D expenses rose by $110.5 million to $550.4 million, with non-GAAP figures reflecting the adjustments including the Cash Bonus Program.
General and Administrative Expenses
General and administrative expenses for the quarter climbed by $39.0 million to reach $147.1 million. This surge was mainly attributed to an increase in share-based compensation, which underscores the company’s investment in long-term equity incentives.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
14098 M
Market cap (USD)
8,923,578
Daily traded volume (Shares)
11.78 / 11.37
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
